GlassScriptPhysician profile
Jody A Maffei
NPI 1134707524
$6,061.17
in general payments reported to CMS, 2019-2025
25 companies · $724 in 2025
The $724 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $818 · 2022: $1,594 · 2023: $1,543 · 2024: $1,382 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,465 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,464.61 |
| Education | $184.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,691.84 | 2021-2025 | |
| Genzyme Corporation | $610.12 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $543.33 | 2022-2025 | Dupixent, Libtayo |
| Journey Medical Corporation | $457.37 | 2021-2025 | |
| Leo Pharma INC. | $456.01 | 2021-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $388.75 | 2023-2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $306.84 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $278.09 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| Almirall LLC | $262.97 | 2021-2022 | |
| Epi Health, LLC | $191.78 | 2022 | |
| Sun Pharmaceutical Industries INC. | $189.97 | 2023-2024 | Blu-U, Odomzo, Winlevi |
| Galderma Laboratories, L.P. | $118.88 | 2022-2025 | Nemluvio |
| Ucb, INC. | $98.78 | 2025 | Bimzelx |
| Incyte Corporation | $82.72 | 2022-2025 | Opzelura |
| Medtronic, INC. | $80.20 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Mayne Pharma Commercial LLC | $63.06 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $49.36 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.27 | 2023 | Arazlo, Duobrii, Jublia |
| Amgen INC. | $16.85 | 2024 | Otezla |
| Janssen Biotech, INC. | $15.81 | 2023 | Tremfya |
| Verrica Pharmaceuticals INC. | $15.13 | 2024 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $14.91 | 2021 | |
| Dermavant Sciences, INC. | $14.07 | 2024 | Vtama |
| Nabriva Therapeutics, Plc | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jody Maffei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.